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Abstract
Summary Serious adverse events of infections that occurred
in subjects receiving denosumab or placebo in the Fracture
Reduction Evaluation of Denosumab in Osteoporosis every
6 Months (FREEDOM) study were examined in detail.
Serious adverse events of infections in denosumab subjects
had heterogeneous etiology, with no clear clinical pattern to
suggest a relationship to time or duration of exposure to
denosumab.
Introduction Denosumab reduces the risk for new vertebral,
hip, and nonvertebral fractures compared with placebo. In
the pivotal phase 3 fracture trial (FREEDOM), the overall
safety profile and incidence of adverse events including
adverse events of infections were similar between groups.
Serious adverse events of erysipelas and cellulitis were
more frequent in denosumab-treated subjects. In this report,
we further evaluate the details of infectious events in
FREEDOM to better understand if RANKL inhibition with
denosumab influences infection risk.
Methods FREEDOM was an international multicenter,
randomized, double-blind, placebo-controlled study in
postmenopausal women with osteoporosis randomly
assigned to receive placebo (n= 3 , 9 0 6 )o rd e n o s u m a b
60 mg every 6 months (n=3,902). The incidence of adverse
events and serious adverse events categorized within the
Medical Dictionary for Regulatory Activities system organ
class, “Infections and Infestations,” was compared between
the placebo and denosumab groups by body systems and
preferredterms.Thetemporalrelationshipbetweenoccurrence
of serious adverse events of infections of interest and
administration of denosumab was explored.
Results Serious adverse events of infections involving the
gastrointestinal system, renal and urinary system, ear, and
endocarditis were numerically higher in the denosumab
group compared with placebo, but the number of events
was small. No relationship was observed between serious
adverse events of infections and timing of administration or
duration of exposure to denosumab.
Conclusions Serious adverse events of infections that
occurred with denosumab treatment had heterogeneous
etiology, with no clear clinical pattern to suggest a
relationship to time or duration of exposure to denosumab.
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RANKL is recognized as an essential factor in the
regulation of bone resorption. By signaling through its
receptor RANK, RANKL increases osteoclast formation,
differentiation, and activity and prolongs osteoclast survival
[1–6]. In clinical trials, denosumab, a RANKL inhibitor,
has demonstrated efficacy to reduce bone resorption,
increase bone mineral density (BMD) and strength in both
cortical and trabecular bone, and reduce the risk of
vertebral, hip, and nonvertebral fractures [7–11].
In addition to expression in bone, RANKL and RANK are
expressed by cells of the immune system including activated
T lymphocytes, B cells, and dendritic cells [3, 12, 13],
suggesting that immune cells might affect bone homeostasis
or that RANKL inhibition might alter immune function.
Gene deletion studies in rodents show that complete absence
of RANKL or its receptor RANK during embryogenesis
leads to absence of lymph nodes and changes in thymus
architecture [3, 14]. However, in both RANKL and RANK
deletion, dendritic cell and macrophage components were
normal. In humans with osteoclast-poor osteopetrosis due to
absence of RANKL and complete loss of function, there
appears to be minimal, if any, effect on immune system
development and function [15].
In studies of genetically modified rodents and in pharma-
cologic experiments in cynomolgus monkeys, inhibition of
RANKL, rather than complete RANKL or RANK ablation,
increased BMD but did not appear to have significant
consequences on basal immune parameters, generation of T
or B cell immune responses, or responses to immunization or
other immune challenges [16–18]. In five distinct preclinical
models of inflammatory arthritis and in a T cell-driven model
of inflammatory bowel disease, RANKL inhibition decreased
bone resorption while having no effect on parameters of
inflammation including local edema, pannus formation, and
cytokine and chemokine profiles or histopathologically
evaluated gut inflammation [19–28].
Some in vitro and in vivo effects of RANKL inhibition
on immune function have been noted in rodents with major
defects in immune system stimulation mechanisms, such as
IL-2 or CD40 depletion [12, 29, 30], which suggests that
there may be redundancy within the immune system, with
the RANKL pathway having a secondary role [29].
Additionally, it has been postulated that the RANKL–
RANK interaction may modify immune responses in
specific tissues such as the skin, potentially through an
effect on the intensity of the inflammatory response, rather
than through an immunosuppressive effect [31, 32].
In a dose-ranging study of denosumab in healthy
postmenopausal women, no clinically meaningful differences
inoveralllymphocytecounts,Tcells,orBcellswereobserved
in subjects treated with denosumab [33]. In the phase 3
international, double-blind pivotal trial demonstrating frac-
ture reduction efficacy of denosumab in postmenopausal
women with osteoporosis (Fracture Reduction Evaluation of
Denosumab in Osteoporosis every 6 Months (FREEDOM)],
the overall incidence of adverse events and serious adverse
events was similar between denosumab- and placebo-treated
subjects; however, some numeric imbalances in specific
events were reported, including serious adverse events of
infections involving the skin [8]. To better understand the
potential influence of RANKL inhibition on infections, we
examined the incidence and types of infections as well as
details of individual cases among participants in the pivotal
phase 3 denosumab fracture trial, which represents 10,826
patient-years of exposure to denosumab.
Materials and methods
Subjects and database
Adverse events and serious adverse events of infections as
reported in the denosumab pivotal phase 3 fracture trial were
examined. The study design and primary results of the study
have been previously reported [8]. Briefly, it was a 3-year
multicenter, international, randomized, double-blind,
placebo-controlled study in 7,808 postmenopausal women
with osteoporosis. Subjects received placebo or denosumab
subcutaneously 60 mg every 6 months (Q6M). The study
was conducted in accordance with the Declaration of
Helsinki, and the protocol was approved by an institutional
review board or ethics committee for each study site. All
subjects provided written informed consent.
Safety was assessed through adverse event reporting for
all women who received at least one dose of investigational
product (3,876 placebo and 3,886 denosumab). Information
about adverse events was collected by investigators at each
study visit. The investigator’s verbatim description of an
adverse event was converted into standardized terminology
based on the Medical Dictionary for Regulatory Activities
(MedDRA) version 11 and entered in the safety database as
preferred terms. Adverse events and serious adverse events
were defined according to regulatory criteria: an adverse
event was defined as any untoward medical occurrence in a
clinical investigation subject administered a pharmaceutical
product and which does not necessarily have a causal
relationship with this treatment. A serious adverse event
was defined as any adverse event that resulted in any of the
following outcomes: death, life-threatening adverse drug
experience, inpatient hospitalization or prolongation of
existing hospitalization, persistent or significant disability/
incapacity, or a congenital anomaly/birth defect. In addition,
any event that did not meet the regulatory definition of a
serious adverse event, but in the opinion of the investigator
328 Osteoporos Int (2012) 23:327–337or sponsor represented a significant medical hazard, was
also considered a serious adverse event.
Adverse events and serious adverse events of infections—
those adverse events categorized in the MedDRA system
organ class “Infections and Infestations”—were evaluated for
this report. This category is broad and includes contagious as
well as noncontagious (e.g., appendicitis, cholecystitis,
diverticulitis) events.
Information about antibiotic treatments was obtained from
case narratives and/or concomitant medication listings.
Microbial classification (bacterial, viral, or fungal) could only
be determined if cultures were collected at the time of event
and culture results were reported by the investigators.
Microbial classification was listed as unknown if cultures
were not collected at the time of event, no organisms were
isolated upon culture, or no culture results were reported.
Serious adverse events of opportunistic infections were
identified by a search of the clinical trial safety database using
predefined MedDRA terms that included fungal and mycobac-
terial infections. The presence of an organism by itself was not
sufficient to qualify an adverse event as a serious opportunistic
infection; events needed to meet the regulatory definition of
serious (described above) and were verified by medical review.
Colonization or localized infections were distinguished from
invasive or disseminated infections. For example, shingles
confined to a single dermatome would not be considered
opportunistic, but herpes zoster infection that was disseminated
or involved multiple dermatomes would be included. Queries
were generated by the sponsor to obtain additional information
from investigators if important case-level detail was missing.
Statistical analysis
Demographic data for all randomized subjects were summa-
rized by treatment group. Safety data were summarized by
actual treatment received. Thus, seven subjects assigned to
placebo who received a single dose of denosumab at some
point during the study were included in the denosumab group
for purposes of safety assessments. Yearly incidence rates of
serious adverse events of infection were calculated. The
temporal relationship between occurrence and resolution of
serious adverse events of infections of interest and adminis-
tration ofinvestigational product was explored. P values were
based on the log-rank test. The analyses did not include any
adjustments for multiplicity and should be considered
exploratory.
Results
Baseline characteristics of subjects enrolled in the pivotal
phase 3 fracture trial have been previously reported [8].
Subjects were primarily Caucasian (93%); the mean (SD)
age was 72.3 (5.2) years and 74% were 70 years of age or
older. As previously reported, the overall incidence of adverse
events of infections was similar between the placebo and
denosumab groups (54.4% vs 52.9%, respectively; P=0.17),
and serious adverse events of infections were reported in
3.4% of placebo subjects and 4.1% of denosumab subjects
(P=0.14) [8].
About 40% of the serious adverse events of infection
(41.3% with placebo and 44.7% with denosumab) were of
mild or moderate severity, although they met the regulatory
definition of “serious adverse events.” Usually, the “serious”
definition was applied due to hospitalization of the subject.
The number of subjects discontinuing the study as a result of
adverse events of infection was low and similar between
treatment groups (four placebo, three denosumab; Table 1).
No increased risk for fatal infections was observed with
denosumab (six placebo, six denosumab; Table 1).
Serious adverse events of infections over time
The incidence ofseriousadverse eventsofinfectionacrossthe
3 years of study was examined. The rate of infection did not
change with increasing duration of denosumab exposure
(Table 2). The rates of known bacterial, viral, and fungal
infections also did not increase with duration of denosumab
exposure (Table 2).
Opportunistic infections
Serious adverse events of opportunistic infections were
prospectively identified as events of interest. The incidence
of serious adverse events of opportunistic infections was low
and similar in the placebo (three [<0.1%]) and denosumab
Table 1 Summary of adverse events and serious adverse events of infection
Placebo (N=3,876), n (%) Denosumab (N=3,886), n (%) P value
Adverse events of infections 2,108 (54.4) 2,055 (52.9) 0.1721
Serious adverse events of infection 133 (3.4) 159 (4.1) 0.1399
Serious opportunistic infection 3 (<0.1) 4 (0.1) 0.7130
AEs of infection leading to study discontinuation 4 (0.1) 3 (<0.1) 0.6979
Fatal infections 6 (0.2) 6 (0.2) 0.9787
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infections was observed. In the placebo group, all three
subjects had tuberculosis (preferred terms of tuberculosis or
pulmonary tuberculosis) and one event was fatal. In the
denosumab group, the opportunistic infections were tuber-
culosis (two subjects), aspergillosis of the face, and
disseminated herpes zoster. No risk factors for the opportu-
nistic infections were identified in these subjects. No
temporal relationship was observed between the occurrence
of these opportunistic infections and administration of the
investigational product (Fig. 1a). Nonserious adverse events
of opportunistic infections were not specifically identified
and categorized as such, but individual terms included
tuberculosis, which was reported as a nonserious adverse
event in four subjects receiving placebo and no subjects
receiving denosumab.
Skin infections
Serious adverse events of infections involving the skin
occurred in 3 (<0.1%) placebo subjects and 15 (0.4%)
denosumab subjects (P<0.05; Table 3). These were not
injection-site reactions. In the denosumab group, most of
these skin infections were cellulitis or clinically diagnosed
erysipelas involving the lower extremities that resolved
with administration of common antibiotics. The overall
incidence of adverse events of cellulitis and erysipelas (i.e.,
both serious and nonserious adverse events) was not
significantly different between treatment groups (0.9%
placebo, 1.2% denosumab) [8]. There was no temporal
association between the onset of serious adverse events of
cellulitis and erysipelas and duration of treatment or time
since last dose of investigational product (Fig. 1b).
Cellulitis and erysipelas are usually caused byStreptococcus
pyogenes, Staphylococcus aureus, and other gram-positive
bacterial infections. In this study, serious adverse events of
cellulitis and erysipelas were diagnosed clinically and not
usually confirmed by culture. A positive S. pyogenes culture
was obtained for 1 of the 12 subjects experiencing a serious
adverse event of cellulitis or erysipelas in the denosumab
group.
A detailed description of the cases of serious adverse
events of cellulitis and erysipelas is provided in Table 4.
The median duration of hospitalization for denosumab
subjects was 5.5 days (range, 1–17 days), and most subjects
responded well to treatment with common antibiotics
(Table 4). Preexisting risk factors including venous ulcers
and skin wounds were reported in 5 of 12 denosumab
subjects reporting serious adverse events of cellulitis and
erysipelas.
No subjects in either group discontinued treatment due to
skin infection, and in only one subject was a recurrent serious
adverse event of skin infection observed (denosumab subject
7; Table 4). This subject had a history of varicose ulceration
of a lower extremity before starting the study and experienced
serious adverse events of lower left limb erysipelas, lower
right limb skin ulcer, and lower right limb cellulitis over the
course of the study, with the first event occurring on study
day 39. One subject with a confirmed neuroendocrine
carcinoma of pancreas experienced a fatal event associated
with cellulitis of the right leg; the case was complicated by
sepsis, shock, and multiple organ failure (denosumab subject
5; Table 4).
Gastrointestinal infections
Serious adverse events of infections were also examined in
more detail according to body system. Serious adverse events
of infections involving the gastrointestinal system occurred in
28 (0.7%) placebo subjects and 36 (0.9%) denosumab
subjects (Table 5). The preferred terms categorized under
the gastrointestinal body system correspond to infections
with heterogeneous etiology, and no consistent pattern was
observed in the type of infections. For individual preferred
Table 2 Incidence of serious
adverse events of infections
by year of study and microbial
classification
Year 1 Year 2 Year 3
Incidence of serious adverse events of infection by year
Placebo 42 (1.1%) 49 (1.3%) 47 (1.4%)
Denosumab 55 (1.4%) 58 (1.6%) 54 (1.5%)
Positively identified bacterial infections
Placebo 10 (0.3%) 12 (0.3%) 10 (0.3%)
Denosumab 13 (0.3%) 15 (0.4%) 19 (0.5%)
Positively identified viral infections
Placebo 0 (0.0%) 1 (<0.1%) 5 (0.1%)
Denosumab 2 (0.1%) 4 (0.1%) 2 (0.1%)
Positively identified fungal infections
Placebo 1 (<0.1%) 0 (0.0%) 0 (0.0%)
Denosumab 1 (<0.1%) 0 (0.0%) 1 (<0.1%)
330 Osteoporos Int (2012) 23:327–337terms, the difference between treatment groups was 0.1% or
less. The most common events were gastroenteritis, diver-
ticulitis, and appendicitis.
For subjects with serious adverse events of diverticulitis
(six placebo, eight denosumab), the median hospital stay was
similar between groups, 6 days (range, 1–8 days) for placebo
subjects and 4 days (range, 1–15 days) for denosumab
subjects. No subject in the placebo group and three subjects
in the denosumab group had a history of diverticulitis before
entering the study. One denosumab subject experienced two
serious adverse events of diverticulitis on study.
Renal and urinary infections
Serious adverse events of infections involving the urinary
tract were experienced by 20 (0.5%) placebo subjects and
Placebo Subject 3
Placebo Subject 2
Placebo Subject 1
Denosumab Subject 4
Denosumab Subject 3
Denosumab Subject 2
Denosumab Subject 1
Placebo Subject 1
Denosumab Subject 12
Denosumab Subject 11
Denosumab Subject 10
Denosumab Subject 9
Denosumab Subject 8
Denosumab Subject 7
Denosumab Subject 6
Denosumab Subject 5
Denosumab Subject 4
Denosumab Subject 3
Denosumab Subject 2
Denosumab Subject 1
Denosumab Subject 3
Denosumab Subject 2
Denosumab Subject 1
Baseline M6 M12 M18 M24 M30 M36 Baseline M6 M12 M18 M24 M30 M36
Baseline M6 M12 M18 M24 M30 M36
indicates timing of administration of denosumab 60 mg Q6M
indicates timing of administration of placebo
indicates timing of administration of denosumab 60 mg Q6M
indicates timing of administration of denosumab 60 mg Q6M
indicates timing of administration of placebo
ab
c
Fig. 1 a Serious adverse events of opportunistic infections and
relationship to timing of administration of investigational product. b
Serious adverse events of cellulitis and erysipelas and relationship to
timing of administration of investigational product. Denosumab subject 5
experienced a fatal adverse event associated with cellulitis. c Events of
endocarditis and relationship to timing of administration of investigational
product. Denosumab subjects 1 and 2 experienced serious adverse events
of endocarditis; denosumab subject 3 experienced a nonserious adverse
event of endocarditis. Circles indicate denosumab injections; plus signs
indicate placebo injections; rectangles indicate onset and duration of the
adverse event
Osteoporos Int (2012) 23:327–337 33129 (0.7%) denosumab subjects (Table 5). The most
common serious adverse events included urinary tract
infection, cystitis, and pyelonephritis. Culture results
indicated these were typically due to Escherichia coli and
other common gram-negative bacteria. The difference in
incidence between treatment groups for individual preferred
terms was 0.1% or less.
Ear infections
Serious adverse events of infections involving the ear
occurred in no placebo subjects and five denosumab subjects
(Table 5). These infections were primarily labyrinthitis (four
cases), of which two cases were moderate and two were
severe; the other serious adverse event was otitis media.
Resolution of labyrinthitis occurred within 2 and 13 days in
cases of moderate severity and in 6 weeks in a severe case.
In one subject with a history of recurrent labyrinthitis, the
event was ongoing. No apparent relationship was observed
between onset of the events and time since initiation of
denosumab (range, 6–31 months).
Most subjects with serious adverse events of ear
infections had preexisting complicating factors. For example,
three of the four subjects with labyrinthitis had a prior history
of labyrinthitis. The subject with otitis media had a previous
stapedectomy and tympanoplasty in the same ear approxi-
mately 3 years prior. She was hospitalized for an exploratory
tympanoplasty.
Endocarditis
Three events of endocarditis (one adverse event and two
serious adverse events) were reported in the denosumab
group and none in the placebo group. No relationship was
observed between the onset of endocarditis and the duration
of treatment or time since last dose of denosumab (Fig. 1c),
and a causative pathogen was not identified in any case.
Two of the subjects underwent echocardiography and the
diagnosis was reported to be confirmed. One of these
subjects was hospitalized for treatment with antibiotics and
the other was treated as an outpatient. In the third subject,
acute bacterial endocarditis was suspected as a probable
contributor to a fatal event of multiorgan failure; no
treatment details from the case were available, including
echocardiography, and an autopsy was not performed.
Respiratory, mediastinal, and other thoracic infections
Serious adverse events of infections involving the respiratory
tract occurred in 68 (1.8%) placebo subjects and 69 (1.8%)
denosumab subjects (Supplementary Table 1). Incidence of
individual preferred terms was similar between groups.
Osteomyelitis
One subject in each treatment group experienced a
nonserious adverse event of osteomyelitis of the jaw. Both
cases were adjudicated negative for osteonecrosis of the
jaw. The denosumab subject received only one dose of
denosumab on study; the event occurred 2 years after
denosumab administration.
Peripheral white blood cell counts
Neutrophil, lymphocyte, and monocyte counts were similar
between the placebo and denosumab groups throughout the
study (Supplementary Fig. 1). Cell counts did not change
with increased duration of denosumab exposure.
Discussion
This study examined the incidence, types, and details in
individual subjects of adverse events of infections observed in
postmenopausal women treated with the RANKL inhibitor
denosumab or placebo in the phase 3 pivotal fracture trial,
which represents more than 10,000 patient-years of denosumab
exposure. The overall incidence of infections was similar
Table 3 Incidence of serious adverse events of skin infection
Placebo (N=3,876)
a, n (%) Denosumab (N=3,886)
a, n (%)
Serious adverse events of infection involving the skin 3 (<0.1) 15 (0.4)*
Cellulitis and erysipelas 1 (<0.1) 12 (0.3)
b
Skin bacterial infection 0 (0) 2 (<0.1)
Staphylococcal infection 1 (<0.1) 1 (<0.1)
Infected skin ulcer 0 (0) 1 (<0.1)
b
Subcutaneous abscess 1 (<0.1) 0 (0)
*P<0.05 vs placebo
aNumber of subjects who received ≥1 dose of investigational product
bOne subject in the denosumab group experienced events of cellulitis and erysipelas and infected skin ulcer
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Osteoporos Int (2012) 23:327–337 333between treatment groups. No increased risk of opportunistic
infection was seen with denosumab.
Serious adverse events of cellulitis and erysipelas
resulting in hospitalization occurred more frequently with
denosumab, although the number of events was low.
Hospitalized subjects responded to treatment with common
antibiotics. No significant increase in overall incidence
(serious and nonserious adverse events) of cellulitis and
erysipelas was observed with denosumab. With the small
numbers of subjects, the finding of more hospitalizations in
thedenosumabgroupmightbeduetochanceorcouldindicate
that skin infections were more severe with denosumab
treatment. Preclinical data suggest another possibility: inhibi-
tion of RANKL in keratinocytes may decrease the number of
regulatory T cells (cells that suppress immune responses),
leading toan increased inflammatoryresponse inthe skin[31,
32]. Thus, it may be that the appearance of the skin lesions
was suggestive of greater severity of the inflammatory
process in subjects receiving denosumab, resulting in more
frequent hospitalization.
Table 5 Incidence of serious adverse events of infections related to the gastrointestinal, renal and urinary, and ear and labyrinth body systems
Placebo (N=3,876)
a,
n (%)
Denosumab (N=3,886)
a,
n (%)
P value
Serious adverse events of infections related to the gastrointestinal system 28 (0.7) 36 (0.9) 0.3322
Gastroenteritis 7 (0.2) 9 (0.2)
Diverticulitis 6 (0.2) 8 (0.2)
Appendicitis 7 (0.2) 7 (0.2)
Abdominal abscess 0 (0) 2 (0.1)
Helicobacter infection 0 (0) 2 (0.1)
Clostridium difficile colitis 2 (0.1) 1 (<0.1)
Anal abscess 0 (0) 1 (<0.1)
Biliary tract infection fungal 0 (0) 1 (<0.1)
Gastric infection 0 (0) 1 (<0.1)
Gastroenteritis Escherichia coli 0 (0) 1 (<0.1)
Gastroenteritis bacterial 0 (0) 1 (<0.1)
Gastroenteritis rotavirus 0 (0) 1 (<0.1)
Gastroenteritis viral 0 (0) 1 (<0.1)
Post procedural infection 0 (0) 1 (<0.1)
Salmonellosis 2 (0.1) 0 (0)
Abscess intestinal 1 (<0.1) 0 (0)
Gastrointestinal infection 1 (<0.1) 0 (0)
Infected cyst 1 (<0.1) 0 (0)
Peridiverticular abscess 1 (<0.1) 0 (0)
Peritoneal abscess 1 (<0.1) 0 (0)
Typhus 1 (<0.1) 0 (0)
Serious adverse events of infections related to the renal and urinary systems 20 (0.5) 29 (0.7) 0.2105
Urinary tract infection 10 (0.3) 16 (0.4)
Cystitis 2 (0.1) 6 (0.2)
Pyelonephritis 2 (0.1) 5 (0.1)
Urosepsis 2 (0.1) 1 (<0.1)
Pyelonephritis acute 1 (<0.1) 1 (<0.1)
Pyelonephritis chronic 0 (0) 1 (<0.1)
Escherichia infection 2 (0.1) 0 (0)
Bacterial pyelonephritis 1 (<0.1) 0 (0)
Kidney infection 1 (<0.1) 0 (0)
Renal abscess 1 (<0.1) 0 (0)
Serious adverse events of infections related to the ear and labyrinth systems 0 (0) 5 (0.1) 0.0260
Labyrinthitis 0 (0) 4 (0.1)
Otitis media 0 (0) 1 (<0.1)
aNumber of subjects who received ≥1 dose of investigational product
334 Osteoporos Int (2012) 23:327–337When serious adverse events of infections were reviewed
according to body systems, events involving the abdomen,
urinary tract, and ear, as well as endocarditis, were numeri-
cally more frequent in denosumab than placebo subjects,
while serious adverse events of infections of the respiratory
tract were balanced between treatment groups. The body
system groupings were broad and included contagious as well
as noncontagious events. In general, when numerical imbal-
ances were reported—for example, ear and labyrinthitis
events—subjectshadpreexistingriskfactorsforthecondition.
Given the age of the study population, many had multiple
comorbidities including preexisting conditions that may have
predisposed to the type to infections observed. Although
general medical histories were collected from all subjects at
study start, information relating to such potentially predispos-
ing comorbid conditions was not collected systematically.
Therefore, we were unable to determine from the available
data if the overall baseline level for certain risk factors was
similar between groups. Similarly, we could not conclusively
investigatewhetherpatientswithparticularbaselinecharacter-
istics might be at increased risk to develop certain infections
with denosumab.
In denosumab-treated subjects, white blood cell counts
remained stable over time and similar to placebo. Serious
adverse events of infections that occurred with denosumab
had heterogeneous etiology, with no clear clinical pattern to
suggest a relationship to time or duration of exposure to
denosumab. In aggregate, these findings are consistent with
the evidence that suggests there is a redundancy of function
in the adult immune system, with RANKL playing a
minimal role [34] and inhibition of RANKL having little
or no adverse effect in this regard.
Denosumab safety has been evaluated across the clinical
development program. In a small phase 3 trial comparing
denosumab and placebo in a younger population (mean age,
59years)of332postmenopausalwomenwithlowbonemass,
subjects treated with denosumab had significantly more
serious adverse events of infections that were associated with
hospitalization [7]. The serious adverse events of infections
were common infections for the population studied and were
treated successfully with standard antibiotics; no pattern was
observed in the type of body systems affected. No
significantly increased risk of serious adverse events of
infections was observed in any other phase 2 and phase 3
clinical trials of denosumab compared with placebo or
alendronate in postmenopausal women with low bone mass
[7, 35–37].
Denosumab has also been studied in other disease
populations. No increased risk of infection with denosumab
(60 or 180 mg Q6M) was noted in clinical trials of patients
with rheumatoid arthritis receiving methotrexate or in patients
receiving hormone ablation therapy for breast or prostate
cancer (denosumab 60 mg Q6M) [38–40]. Similarly, no
increased risk of infection was observed for a higher dose of
d e n o s u m a b( 1 2 0m ge v e r y4w e e k s )c o m p a r e dw i t h
zoledronic acid in several large trials in patients with
advanced cancer or multiple myeloma and bone metastases
[41–43].
In this analysis, we endeavored to develop a better
understanding of the effects of RANKL inhibition with
denosumab by evaluating infectious events in postmenopausal
women with osteoporosis participating in the phase 3 pivotal
fracture trial. Although this study represents the largest
placebo-controlled trial with denosumab, it was not designed
forevaluatingstatisticaldifferencesbetweengroupsofsubjects
who experienced adverse events where the number of events
withinapreferredtermwaslow.Theanalysisofadverseevents
reported in a clinical trial relies on the mappingof investigator-
provided terms for diagnoses to standardized terminology
using a coding dictionary (MedDRA). This process can
introduce a categorization bias when verbatim terms are
groupedtogetherintopreferredtermsbaseduponthejudgment
of the coding personnel. When these data are evaluated in
aggregate, diagnostic subtlety may be lost, thus, apparent
differences in outcome may reflect the lumping of verbatim
terms into MedDRA categories as well as actual differences in
the data.
The benefit/risk profile of denosumab continues to be
evaluated in ongoing clinical trials, including an open-label
extension of the phase 3 pivotal fracture trial that is planned
to follow up subjects for up to 10 years. Over the first
3 years (reported here), there is no indication that inhibition
of RANKL has any effect on defense mechanisms against
infection. A preliminary report indicates that the safety
profile of denosumab remains consistent over 5 years of
treatment, with no evidence of an increase in the rate of
infectious events over time [44].
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